ESR1 and breast carcinoma: Based on this score, we conservatively estimate that, of 925 ER+ breast cancer patients in the TCGA dataset, 122 have high expression of at least one of the RET ligands (13%), 57 of which had high levels of GDNF (Fig 5F).